Introduction
Fine spatial and temporal regulation of genes is required for cell growth, differentiation, and development.
Selective gene activation, the quantitative level of gene expression, and the order by which genes are either repressed or activated are the basis of sophisticated processes in embryonic development.
Chromatin, the DNA-proteins complex in the nucleus, acts as a platform capable of fine integration of cellular signals. Thus, chromatin dynamics, along with transcription factors and cofactors, plays a central role in gene regulation during development (Arney and Fisher, 2004) .
Retinoic acid (RA) is a major cell signal, which dynamically regulates the chromatin structure of cellular genes characterized by specific regulatory sequences, the RA-responsive elements (RARE). The direct or indirect regulation of genes by the RA signal controls fundamental cellular processes and, ultimately, developmental processes (Chambon, 1996) . RA can influence the chromatin structure of target genes by binding to specialized transcription factors, the RA receptors (RARs). RARs can heterodimerize with the rexinoid receptors, RXRs, and upon RA binding, they can recruit coactivator protein complexes and chromatin remodeling complexes. These complexes can impose critical histone modifications, such as acetylation of specific lysine residues, and lead to conformational changes of the chromatin, ultimately enabling transcriptional activation by the RNA Polymerase II (Pol II) (Dilworth and Chambon, 2001) .
The intracellular level of RA is regulated by RA itself through a coordinated group of proteins involved in the metabolism of RA and its precursor, retinol (Napoli, 1999) . We hypothesized that both RARs and RAREcontaining genes involved in retinol/RA metabolism are part of an interconnected epigenetic network (Sirchia et al., 2000) . Consequently, events capable of interfering with RAR-mediated transcriptional regulation by RA should lead to aberrant repression of RA-responsive genes implicated in RA metabolism/homeostasis.
To test this hypothesis we used a model comprising the P19 and RAC65 embryonal carcinoma cell lines. P19, which carries a normal RARa, is growth-inhibited and can differentiate into neurons in response to RA (Jones-Villeneuve et al., 1982; Edwards and McBurney, 1983) . In contrast, its mutant counterpart, the RAC65 cell line, is RA-resistant and cannot differentiate when grown as aggregates (Jones-Villeneuve et al., 1983) . RAC65 harbors a mutant RARa protein, originally designated RARa 0 (Pratt et al., 1990) . The wild-type RARa has six distinct protein domains, A-F, including the C domain, capable of binding the RARE of target genes, and the E domain harboring the RA-binding domain (Laudet and Gronemeyer, 2002 and references within). The mutant RARa 0 lacks part of the E-domain ( Figure 1a ) as a consequence of a genetic insertion in the wild type RARa, but retains the C domain. The biological features of RAC65 are mostly due to the defective RARa 0 , which exerts a dominant negative action on the wild type RARa (Pratt et al., 1990; Kruyt et al., 1992) . RARa 0 prevents the transactivation of RA-responsive genes resulting in a block of neuron differentiation in response to RA (Kruyt et al., 1992; Costa and McBurney, 1996) . Expression of RARa 0 in P19 cells can markedly repress the induction of another RA-receptor gene, RARb2, in response to RA (Kruyt et al., 1992) . Here we show that in RAC65 cells RARb2 is transcriptionally repressed as well as the cytochrome P450 Cyp26a1, encoding for the RA hydrolase involved in the conversion of RA to polar compounds (Ray et al., 1997; White et al., 2003) . Notably, the CpG islands associated with both RARb2 and Cyp26a1 repressed chromatin do not show any aberrant CpG methylation. Moreover, we show that Cyp26a1 transcriptional inactivity is consequent to RARb2 transcriptional downregulation. This conclusion is based on the evidence that stable RARb2 transcriptional knockdown by RNA interference in P19 cells leads to Cyp26a1 transcriptional repression, marked by histone repressive modifications but not DNA methylation, similarly to what we found in RAC65 cells. Cyp26a1 downregulation was concomitant with an impaired growth inhibition and differentiation in response to RA. Cyp26a1-regulated RA catabolism likely represents a critical differentiation switch in embryocarcinoma cells (Sonneveld et al., 1999) . Based on our findings, the differentiated phenotype would be epigenetically regulated in response to RA through a network connecting the two RA receptors with the Cyp26a1 RA hydrolase.
Results
The endogenous dominant-negative RARa 0 mutant of RAC65 is associated with both RARb2 and Cyp26a1 epigenetic silencing RAC65 cells contain an endogenous RARa 0 mutant lacking the RA-binding domain (Figure 1a ). In these cells RA can induce significantly (Po0.001) lower levels of transcription of both RARb2 (Figure 1b , left) and Cyp26a1 (Figure 1b , right) than in P19 cells, with a normal RARa. Consistently, chromatin immunoprecipitation (ChIP) analysis of both RARb2 and Cyp26a1 promoter regions (encompassing the RARE, TATA, and transcription start site) and two flanking control regions (positioned 1 Kb upstream and 1 Kb downstream of each RARE; Figure 1c , top) showed that RNA Pol II specifically binds the transcription start site of both RARb2 and Cyp26a1 but not the flanking À1 Kb and þ 1 Kb regions, in P19 cells in response to RA (Figure 1c, middle) . Conversely, occupancy of both RARb2 and Cyp26a1 transcription start sites by Pol II was not detected in RAC65 (Figure 1c, middle) .
By ChIP analysis of the RARb2 and Cyp26a1 regions encompassing the RARE, TATA box, and transcription start sites, we showed that (i) the level of methylation of lysine 9 of histone H3 (Me-H3K9) -a hallmark of repressive chromatin (Berger, 2002 (Figure 1c , bottom). Bisulfite sequencing of both RARb2 and Cyp26a1 CpG-islands associated with repressed RARb2 and Cyp26a1 alleles did not detect any aberrant CpG methylation, whereas the corresponding CpG islands of the control 4T1 mouse cell line were fully methylated (Figure 1d ). Consistently, the demethylating agent 5-Aza-2 0 -deoxycytidine did not restore either RARb2 or Cyp26a1 transcription (data not shown). Apparently, heritable repressive states of both RARb2 and Cyp26a1 were achieved in the absence of DNA methylation.
RARb2 binds the Cyp26a1-RARE Based on the concomitant epigenetic downregulation of both RARb2 and Cyp26a1 in RAC65 cells, we hypothesized that while RARb2 is downregulated because of lack of RA-signal integration at RARb2 chromatin through RARa 0 , Cyp26a1 is downregulated because of lack of RA-signal integration at Cyp26a1 due to lack of the RARb2 receptor. By using antibodies specifically recognizing either RARa or RARb2 overexpressed in COS-1 cells (Figure 2a ), we found that RARa specifically binds the P19 RARb2 region encompassing the RARE, but not two flaking regions, one upstream (À1 Kb) and one downstream ( þ 1 Kb) of the RARE-containing region (ChIP anti-RARa, Figure 2b , left). Upon RARb2 induction in response to RA (1 mM, for 24 h), RARb2 binds not only its own RARE region (ChIP anti-RARb, Figure 2b , middle), as expected since RARb2 regulates its own transcription (Chiba et al., 1997) , but also the Cyp26a1 RARE (ChIP anti-RARb, Figure 2b , right). Thus, RARb2 binds Cyp26a1 in response to RA.
RARb2-knockdown by RNA interference in P19 cells induces Cyp26a1 epigenetic downregulation Next, we tested whether RARb2-knockdown in P19 cells leads to Cyp26a1 downregulation. We stably transfected P19 cells with pSUPER-retro vectors containing either one of two RARb2-targeting sequences that efficiently silenced exogenous RARb2 transcription in COS-1 cells (see Materials and methods). We isolated six independent P19 clones with markedly downregulated RARb2 transcription including sib-C8 and sib-C9 (Figure 2c ). RA-induced Cyp26a1 transcription was significantly (Po0.001) downregulated in both sib-C8 and sib-C9 relative to the transcription of two representative control P19 clones, C4 and C7, carrying the cognate empty vector ( Figure 2d ). As shown for the P19 clone sib-C9, RARb2-knockdown did not affect the binding of RARa to the RARb2 promoter region containing the RARE (Figure 2e , left), whereas RARb2 was not present on the Cyp26a1 promoter region containing the RARE in response to RA (Figure 2e, right) .
ChIP analysis of the Cyp26a1 RARE-containing region with antibodies against Pol II, Ac-H4, and , bottom) assays we found that the RARb2-knockdown P19 clones sib-C8 and sib-C9 are significantly (Po0.05) less growthinhibited by RA (0.01-0.1 mM, 72 h) than the control P19 clones C4 and C7. These data demonstrate that decreased responsiveness to the growth-suppressive activity of RA is indeed consequent to RARb2 downregulation. Cyp26a1 is epigenetically regulated by retinoic acid receptors S Pozzi et al RA-induced differentiation is impaired in RARb2-knockdown P19 aggregates P19 grown as aggregates in suspension can differentiate into neurons in response to RA, while RAC65 are unable to do so (Figure 4a, left) , as shown by the significant difference in the neuron differentiation score (NDS ¼ neurons area/nuclei area, Figure 4a , right). We found that the NDS of the RARb2-knockdown P19 clone sib-C9 was also significantly (0.001oPo0.01) lower than the NDS of the control P19 C4 clone carrying the empty vector, and in the range of the NDS measured in RAC65 cells (Figure 4a, right) . Remarkably, Cyp26a1, which is necessary for embryocarcinoma cell differentiation (Sonneveld et al., 1999) , remains downregulated in RARb2-knockdown P19 clones also when grown as aggregates (Figure 4b ). Apparently, when RA signal cannot be properly integrated through either RARa or RARb2, Cyp26a1 becomes silent and differentiation does no longer occur in response to RA.
Discussion
Here we report that, in the P19 mouse embryocarcinoma cell line, Cyp26a1, a cytochrome P450 gene involved in Figure 3 Decreased RA-induced growth-inhibitory effect in RARb2-knockdown P19 clones. Colony formation (top) and proliferation (bottom) assays show that the growth of both RAC65 cells and RARb2-knockdown sib-C8 and sib-C9 clones is significantly less inhibited by RA than the growth of P19 wild-type cells and control C4 and C7 clones. Cyp26a1 is epigenetically regulated by retinoic acid receptors S Pozzi et al RA catabolism, is epigenetically regulated at chromatin level by RARb2, a RA-receptor that is in turn epigenetically regulated by the RA-receptor RARa. The P19 cell line is growth-inhibited and can differentiate into neurons in response to RA. In contrast, the P19-derived RAC65 cell line, which contains a mutant RARa (RARa 0 ) and shows a significant epigenetic downregulation of both RARb2 and Cyp26a1, cannot do so.
It was previously reported that the exogenous expression of a mutated RARa, identical to the RAC65 RARa 0 mutant, in P19 cells leads to marked downregulation of a number of endogenous RAresponsive genes (Costa and McBurney, 1996) . We observed that RAC65 RARb2-chromatin is transcriptionally inactive (Pol II was not detected at the transcription start site in response to RA) and marked by aberrant levels of repressive histone modificationsnamely methylation of H3K9 and hypoacetylation of histone H4 -of the chromatin associated with the RARb2-RARE region. This was also the case for RAC65 Cyp26a1 chromatin. In the absence of RA, the RARa receptor binds the RARb2-RARE, and in turn RARb2 binds the RARE of the P19 Cyp26a1 promoter in response to RA. These data and the finding that in RARb2-knockdown P19 clones Cyp26a1 chromatin becomes transcriptionally inactive make us conclude that the inability of integrating RA signal through either RARa (as in RAC65 cells) or RARb2 (as in the RARb2-knockdown clones) leads to stable epigenetic repression of Cyp26a1. Concomitantly with Cyp26a1 repression, cells are less sensitive to the growth-suppressive activity of RA and lose neuron differentiation potential. This evidence supports the supposition that Cyp26a1, which is critical for P19 differentiation (Sonneveld et al., 1999) , may act as an epigenetic switch capable of controlling differentiation by regulating the intracellular level of RA and its catabolites (Dobbs-McAuliffe et al., 2004) . Further work is required to establish whether and how RA catabolism can affect RA-induced differentiation of embryocarcinoma cells.
Given the link between differentiation and cancer, we searched for evidence of concomitant loss of RARs and Cyp26a1 silencing also in human cancer cell differentiation models. A few genetic mutations involving RARa were indeed reported in cancer cells and found associated with either RARb2 or Cyp26a1 downregulation. PML-RARa, an oncogenic protein associated with acute promyelocitic leukemia, which leads to block of myeloid maturation both in vitro and in vivo (He et al., 1998; Grignani et al., 2000) , was shown to induce epigenetic repression of RARb2 in the presence of DNA methylation (Di Croce et al., 2002) . However, we show that in embryocarcinoma cells RARb2 silencing can occur also by virtue of an accumulation of repressive Another nonfunctional RARa mutant characterized by a point mutation affecting the ligand-binding domain, was found associated with both block of myeloid maturation and Cyp26a1 silencing in HL60 promyelocitic leukemia cell derivatives (Ozpolat et al., 2002) . RARa mutants can apparently induce both RARb2 and Cyp26a1 transcriptional downregulation indicating the existence of a coordinated epigenetic network linking RARa, RARb2 and Cyp26a1. Similarly, the differentiation programs of several cell types may be affected by alterations of RA-controlled epigenetic networks, as it happens in RAC65 embryocarcinoma cells where RARa 0 apparently triggers an epigenetic repressive domino effect ( Figure 5 ).
The identification of coordinated epigenetic networks can clarify the epigenetic aspects of developmental processes as well as the nonrandom nature of epigenetic repressive changes associated with gene silencing in cancer (Baylin and Bestor, 2002) .
Materials and methods

Drugs
All-trans-RA (Sigma, St Louis, MO, USA) and TSA (Sigma) were dissolved in absolute ethanol. 5-Aza-2 0 -deoxycytidine (Sigma) was dissolved in 0.45% NaCl containing 10 mM sodium phosphate (pH 6.8).
Cell lines and cell cultures
Mouse embryocarcinoma cell lines P19 (ATCC, Manassas, VA, USA) and RAC65 cells, a kind gift of Dr P van der Saag (Hubrecht Laboratory, Utrecht, The Netherlands), were grown in DMEMa containing L-glutamine and 7.5% charcoalstripped FBS at 371C in 5% CO 2 . Colony formation assay was performed essentially as described (Sirchia et al., 2002) . For proliferation assay, cells were seeded in 96-well plates. In all, 12 replicates were processed for each treatment, in three independent experiments, using the Calcein AM/EthD-III Viability/Cytotoxicity Assay Kit (Molecular Probes-Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Statistical significance was calculated by using the Student's t-test.
Neuron differentiation assay
To test for neural differentiation, untransfected and transfected P19 and RAC65 cells were seeded at the density of 5 Â 10 4 per ml, in microbiological-grade Petri plates, and allowed to aggregate for 3 days prior to treatment with 0.1 mM RA for 72 h, as described (Martin and Evans, 1975) . At the end of treatment, cellular aggregates were washed with RAfree medium, seeded in eight-well chambers and allowed to grow for 72 h. For neuron detection, cells were incubated with the mouse monoclonal anti-bIII tubulin antibody (Abcam, Cambridge, MA, USA), a specific marker for early neuron differentiation. A goat anti-mouse Alexa 546-conjugated (Molecular Probes) was used as a secondary antibody. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI, Sigma). Images were captured using a Nikon TE2000-E inverted microscope. Quantitative analysis of pixel area and intensity was performed using Image J software (NIH) for either nuclei or neurons. The 'neuron differentiation score' (NDS) was calculated as neurons area/nuclei area.
Images from 10 cellular aggregates per each replica of three independent experiments were analysed. Statistical significance was calculated with the Student's t-test.
RNA interference
Two 19-nucleotides sequences (5 0 -TAG CTG GCT TGT CTG TCA TAA TT-3 0 and 5 0 -AAG GGG CAG AGT TTG ATG GAG TT-3 0 ), corresponding to nucleotides 1059-1081 and 1127-1149, respectively, of the mouse RARb2 promoter and 5 0 UTR (GenBank X56850) were inserted in the pSUPER-retro (OligoEngine, Seattle, WA, USA) according to the manufacturer's instructions. The silencing efficiency of the two resulting constructs, pSUPER-RARb2 (sib), was first tested on exogenous RARb2 by transiently cotransfecting COS-1 cells with both pcDNA3.1-hRARb2, encoding the human RARb2, and pSUPER-RARb2 at different ratios. Cotransfection with both pcDNA3.1-hRARb2 and pSUPER-retro was used as a control. Transfections were performed with Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA). Independent clones selected in 2 mg/ml puromycin (Sigma) were tested for RARb2 silencing by real-time RT-PCR. Both sequences were equally efficient in silencing RARb2 transcription. DNA methylation analysis DNA was isolated with DNAzol (Invitrogen) and sodium bisulfite modification was performed as we previously described (Sirchia et al., 2000) . Modified DNA was used for sequencing analysis of RARb2 and Cyp26a1 regulatory regions. A 724-bp region, encompassing 41 CpG dinucleotides in the RARb2 regulatory region, was amplified by nested PCR using specific primer sets (RARb2 sense 1 5 0 -GGG TTT TTG ATG GGT AGT T-3 0 , RARb2 antisense 1 5 0 -CTA ACA AAA CAT CCA TAC AAT CAA ACA TA-3 0 ; RARb2 sense 2 5 0 -GGG TTT GGT TAG GAA TAG GAG AGT-3 0 , RARb2 antisense 2 5 0 -ATC CAC AAA CTC CAT CAA ACT CTA-3 0 ). A 742-bp region, encompassing 50 CpG dinucleotides in the Cyp26a1 promoter, was amplified by PCR using specific primer sets (sense 5 0 -GAG GGA TAG TAG TAG AGA GAT AGT-3 0 , antisense 5 0 -ACC CCT CTT CCA AAC CAT AA-3 0 ). The PCR products were directly sequenced and subsequently cloned in the pCDNA3.1/V5-His vector (Invitrogen). Fifteen to twenty clones for each sample were sequenced.
Real-time RT-PCR
Western blot
Total lysates from COS-1 cells transiently transfected using Lipofectamine Plus (Invitrogen) with pSG5-hRARa1, encoding the human RARa1, or pcDNA3.1-RARb2, encoding the human RARb2, were separated on size by SDS-PAGE followed by electroblotting onto nitrocellulose membrane. Immunodetection was performed with rabbit anti-RARa (C-20, 1:500, Santa Cruz Biotechnology), rabbit anti-RARb (1:500, Active Motif) and rabbit anti-RARb C-19 (1:500, Santa Cruz Biotechnology), followed by appropriate HRPconjugated secondary antibodies (Amersham Biosciences, Pittsburgh, PA) and ECL detection (Amersham Biosciences).
